Navigation Links
Rosetta Genomics Strengthens Senior Management in Preparation for its First Commercial Launch of microRNA-Based Diagnostic Products in 2008
Date:12/3/2007

Appoints Ronen Tamir as Executive Vice President, Marketing and

Communication

REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, December 3 /PRNewswire-FirstCall/ -- Rosetta Genomics (NASDAQ: ROSG) announced today that in preparation for the launch of its first microRNA-based diagnostic products in 2008, it is strengthening its management team. Ronen Tamir has been appointed to the newly created position of Executive Vice President, Marketing and Communication, and will lead the commercialization of the company's first-ever microRNA-based diagnostic products.

"I am very pleased to announce the addition of such an accomplished pharmaceutical executive to our management team," said Amir Avniel, President and CEO of Rosetta Genomics. "Ronen brings with him a successful marketing, investor relations and communications background. His energy and leadership skills will be instrumental to the successful commercialization of our microRNA based products."

Prior to joining Rosetta Genomics, Ronen Tamir was Vice President, Investor Relations for North America at Novartis AG. While Ronen was at Novartis, Novartis significantly increased its North American shareholder base and Ronen's team won numerous awards, including the "Best European IR Team in North America for 2005" by IR magazine, the "Silver Anvil" award by the Public Relations Society of America, and the "Big Apple - Best of the Best" award by the Institution of Public Relations, both for Investor Relations campaign for 2006.

Prior to joining Novartis in 2004, Ronen held several key positions at Serono, including Director of Business Intelligence for North America and Global Product Manager, Neurology, in Geneva, Switzerland, where he oversaw the global launch of Rebif(R), the leading therapy for Multiple Sclerosis. In addition, Ronen was the Regional Product Manager for Neurology and Metabolism for Serono's Intercontinental Business Operations.

Ronen holds a degree in Biology from Bar-Ilan University in Israel and an MBA from Warwick Business School in the UK.

About microRNAs

MicroRNAs (miRNAs) are recently discovered, naturally occurring small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression levels in certain diseased versus normal tissues. As a result, these differences potentially provide for a novel diagnostic strategy for many diseases. MicroRNAs are thought to play a key role in the differentiation of cells into specific cell types performing various functions in the body.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the development of microRNA-based diagnostics and therapeutics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and strategic alliances with leading biotechnology companies, Rosetta Genomics is working to develop a full range of diagnostic and therapeutic products based on microRNAs. The company's primary focus is in the development of microRNA-based products to diagnose and treat different forms of cancer and infectious diseases.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease and the potential of microRNAs in the diagnosis and treatment of disease constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics and therapeutic products, which is unproven and may never lead to marketable products; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its product candidates, all of which are in early stages of development; Rosetta's ability to obtain regulatory approval for products; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2006 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Contact: Media

Alan Zachary

T: +1-312-944-6784

media@rosettagenomics.com

Investors

Juliane Snowden

T: +1-212-213-0006

investors@rosettagenomics.com


'/>"/>
SOURCE Rosetta Genomics Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
3. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test:
4. NeoGenomics, Inc. Schedules its Q3 07 Earnings Conference Call For Wednesday, November 14, 2007 at 11:00 AM
5. NeoGenomics Announces Results for the 3rd Quarter 2007
6. Kenyan malaria success strengthens call for free insecticide-treated nets for all
7. International study strengthens case for daily calcium pill
8. Wachovia Strengthens Its Healthcare Industry Receivables and Cash Management Capabilities
9. Essilor Strengthens its Polarized Lens Distribution Network With the Acquisition of KBco
10. Publicis Groupe Strengthens its Leadership in Digital and Integrated Healthcare Communications in Italy
11. NIAID strengthens and expands Vaccine and Treatment Evaluation Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... On Saturday, ... a treadmill relay – Miles by Moonlight to raise money for the American Heart ... or more. , Teams will work together to keep their treadmills moving for ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in property taxes a year. In some states—like New York, New Jersey, Massachusetts, ... contrast, many overseas retirement havens have extremely low property-tax rates, which contributes to ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- Halo Labs announces the European launch of their new low ... MIBio 2017 in Cambridge, U.K on October ... biopharmaceutical samples with unprecedented speed and sensitivity while using far less ... Imaging. ... analysis system ...
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: